BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schoot TS, Kerckhoffs APM, Hilbrands LB, van Marum RJ. Immunosuppressive Drugs and COVID-19: A Review. Front Pharmacol 2020;11:1333. [PMID: 32982743 DOI: 10.3389/fphar.2020.01333] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Olwal CO, Nganyewo NN, Tapela K, Djomkam Zune AL, Owoicho O, Bediako Y, Duodu S. Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19. Front Immunol 2021;12:602848. [PMID: 33613574 DOI: 10.3389/fimmu.2021.602848] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
2 Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and Myositis: What We Know So Far. Curr Rheumatol Rep 2021;23:63. [PMID: 34216297 DOI: 10.1007/s11926-021-01023-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Farajzadeh S, Ahramiyanpour N. Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID-19 outbreak? Clin Case Rep 2021;9:e04249. [PMID: 34026201 DOI: 10.1002/ccr3.4249] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ateya AM. Clofazimine: A potential therapeutic option for severe COVID-19. Med Hypotheses 2021;150:110535. [PMID: 33735762 DOI: 10.1016/j.mehy.2021.110535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Algarni AS, Alamri NM, Khayat NZ, Alabdali RA, Alsubhi RS, Alghamdi SH. Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations. World J Pediatr 2022. [PMID: 34982402 DOI: 10.1007/s12519-021-00499-w] [Reference Citation Analysis]
6 Chen J, Dai L, Barrett L, James J, Plaisance-Bonstaff K, Post SR, Qin Z. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. Commun Biol 2021;4:682. [PMID: 34083759 DOI: 10.1038/s42003-021-02220-z] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Hasan MJ, Rabbani R, Anam AM, Huq SMR. Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh. Ann Med 2022;54:723-32. [PMID: 35238257 DOI: 10.1080/07853890.2022.2039958] [Reference Citation Analysis]
8 Lennerstrand J, Palanisamy N. Global Prevalence of Adaptive and Prolonged Infections' Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. Viruses 2021;13:1974. [PMID: 34696404 DOI: 10.3390/v13101974] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kates OS, Rakita RM, Lease ED, Fisher CE, Limaye AP. Reply to Authors. Clin Infect Dis 2020:ciaa1633. [PMID: 33104183 DOI: 10.1093/cid/ciaa1633] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Mba IE, Sharndama HC, Osondu-Chuka GO, Okeke OP. Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update. Infect Dis (Lond) 2021;53:559-80. [PMID: 33905282 DOI: 10.1080/23744235.2021.1916071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chan KW, Yu KY, Lee PW, Lai KN, Tang SC. Global REnal Involvement of CORonavirus Disease 2019 (RECORD): A Systematic Review and Meta-Analysis of Incidence, Risk Factors, and Clinical Outcomes. Front Med (Lausanne) 2021;8:678200. [PMID: 34113640 DOI: 10.3389/fmed.2021.678200] [Reference Citation Analysis]
12 Sinha R, Anand S, Singh D, Tripathi S, Shukla P, Singh S, Srivastava P. Bioprocessing strategies for microbial production and purification of immunosuppressants: an insight for process intensification. Chemical Engineering and Processing - Process Intensification 2022. [DOI: 10.1016/j.cep.2022.108797] [Reference Citation Analysis]
13 Philips CA, Rela M, Soin AS, Gupta S, Surendran S, Augustine P. Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients. J Clin Transl Hepatol 2021;9:947-59. [PMID: 34966658 DOI: 10.14218/JCTH.2021.00228] [Reference Citation Analysis]
14 Chen J, Dai L, Barrett L, Post SR, Qin Z. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. bioRxiv 2020:2020. [PMID: 33024968 DOI: 10.1101/2020.10.02.324228] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Chen Y, Guo L, Jiao Y, Fan F, Liu J, Chen M, Yuan H, Lin L, Wang Y. Imaging features of COVID-19: What we can learn from SARS and MERS (Review). Exp Ther Med 2021;21:356. [PMID: 33732329 DOI: 10.3892/etm.2021.9787] [Reference Citation Analysis]
16 Behrangi E, Sadeghzadeh‐bazargan A, Salimi N, Shaka Z, Feyz Kazemi MH, Goodarzi A. Erythrodermic flare‐up of psoriasis with COVID‐19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID‐19 on each other along with the special challenges of the pandemic. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5722] [Reference Citation Analysis]
17 Tabassum T, Araf Y, Moin AT, Rahaman TI, Hosen MJ. COVID-19-associated-mucormycosis: possible role of free iron uptake and immunosuppression. Mol Biol Rep 2021. [PMID: 34709573 DOI: 10.1007/s11033-021-06862-4] [Reference Citation Analysis]
18 Acquavia MA, Pascale R, Pappalardo I, Santarsiero A, Martelli G, Bianco G. Characterization of Quercetin Derivatives in Crossing Combination of Habanero White and Capsicum annuum Peppers and of Anti-Inflammatory and Cytotoxic Activity. Separations 2021;8:90. [DOI: 10.3390/separations8070090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Dotan A, David P, Arnheim D, Shoenfeld Y. The autonomic aspects of the post-COVID19 syndrome. Autoimmun Rev 2022;:103071. [PMID: 35182777 DOI: 10.1016/j.autrev.2022.103071] [Reference Citation Analysis]
20 Gorospe-Sarasúa L, Gallego-Rivera JI, Muñoz-Molina GM, Mirambeaux-Villalona RM, Ajuria-Illarramendi O, González-García A, Barbolla-Díaz I. Delayed Candida Costochondritis and Spondylitis in a Post-COVID-19 Patient Previously Treated With Corticosteroids, Antibiotics, and Tocilizumab. Arch Bronconeumol 2021;57 Suppl 2:48-50. [PMID: 33423872 DOI: 10.1016/j.arbres.2020.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Madhu D, Sharma S, Agarwal A, Saraya A. Special Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots: A Review. J Clin Transl Hepatol 2021;9:568-75. [PMID: 34447687 DOI: 10.14218/JCTH.2021.00001] [Reference Citation Analysis]
22 Mardani M, Hakamifard A. COVID-19 and immunocompromised conditions: Ongoing challenging issue. Eur J Inflamm 2021;19:205873922110161. [DOI: 10.1177/20587392211016114] [Reference Citation Analysis]
23 Dubey A, Dahiya S, Rouse BT, Sehrawat S. Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology. Front Immunol 2020;11:581076. [PMID: 33193385 DOI: 10.3389/fimmu.2020.581076] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Gilhus NE, Verschuuren JJGM, Hovland SIB, Simmonds H, Groot F, Palace J. Myasthenia gravis: do not forget the patient perspective. Neuromuscul Disord 2021:S0960-8966(21)00583-6. [PMID: 34635387 DOI: 10.1016/j.nmd.2021.07.396] [Reference Citation Analysis]
25 Devresse A, De Greef J, Yombi JC, Belkhir L, Goffin E, Kanaan N. Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients. Transplantation Direct 2022;8:e1292. [DOI: 10.1097/txd.0000000000001292] [Reference Citation Analysis]
26 Feldman AG, Danziger-isakov LA. The Impact of COVID-19 on the Pediatric Solid Organ Transplant Population. Seminars in Pediatric Surgery 2022. [DOI: 10.1016/j.sempedsurg.2022.151178] [Reference Citation Analysis]
27 Favà A, Donadeu L, Sabé N, Pernin V, González-Costello J, Lladó L, Meneghini M, Charmetant X, García-Romero E, Cachero A, Torija A, Rodriguez-Urquia R, Crespo E, Teubel I, Melilli E, Montero N, Manonelles A, Preyer R, Strecker K, Ovize A, Lozano JJ, Sidorova J, Cruzado JM, Le Quintrec M, Thaunat O, Bestard O. SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. Am J Transplant 2021;21:2749-61. [PMID: 33756051 DOI: 10.1111/ajt.16570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
28 Yousefghahari B, Navari S, Sadeghi M, Soleimaniamiri S, Soleimaniamiri M, Heidari B, Babaei M, Ghodrati K, Guran A, Gholinia H. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs. Clin Rheumatol 2021. [PMID: 34052904 DOI: 10.1007/s10067-021-05779-4] [Reference Citation Analysis]
29 Kridin K, Schonmann Y, Solomon A, Damiani G, Tzur Bitan D, Onn E, Weinstein O, Cohen AD. Risk of COVID-19 Infection, Hospitalization, and Mortality in Patients with Psoriasis Treated by Interleukin-17 Inhibitors. J Dermatolog Treat 2021;:1-28. [PMID: 33759683 DOI: 10.1080/09546634.2021.1905766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Guo Y, Esfahani F, Shao X, Srinivasan V, Thomo A, Xing L, Zhang X. Integrative COVID-19 biological network inference with probabilistic core decomposition. Brief Bioinform 2021:bbab455. [PMID: 34791019 DOI: 10.1093/bib/bbab455] [Reference Citation Analysis]
31 Lubnow M, Schmidt B, Fleck M, Salzberger B, Müller T, Peschel G, Schneckenpointner R, Lange T, Hitzenbichler F, Kieninger M, Lunz D, Graf B, Brochhausen C, Weber F, Lüke F, Peterhoff D, Schuster P, Hiergeist A, Offner R, Hehr U, Wallner S, Hanses F, Schmid S, Weigand K, Geismann F, Poeck H, Pukrop T, Evert M, Gessner A, Burkhardt R, Herr W, Maier LS, Heudobler D. Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson's disease: Balancing immunosuppression. Int J Infect Dis 2021;103:624-7. [PMID: 33412272 DOI: 10.1016/j.ijid.2020.12.047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
32 Lariccia V, Magi S, Serfilippi T, Toujani M, Gratteri S, Amoroso S. Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. J Clin Med 2020;9:E4021. [PMID: 33322733 DOI: 10.3390/jcm9124021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Asplund Högelin K, Ruffin N, Pin E, Månberg A, Hober S, Gafvelin G, Grönlund H, Nilsson P, Khademi M, Olsson T, Piehl F, Al Nimer F. Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. iScience 2021;24:103078. [PMID: 34490414 DOI: 10.1016/j.isci.2021.103078] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
34 Xiang Y, Wong KC, So HC. Exploring Drugs and Vaccines Associated with Altered Risks and Severity of COVID-19: A UK Biobank Cohort Study of All ATC Level-4 Drug Categories Reveals Repositioning Opportunities. Pharmaceutics 2021;13:1514. [PMID: 34575590 DOI: 10.3390/pharmaceutics13091514] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kridin K, Schonmann Y, Weinstein O, Schmidt E, Ludwig RJ, Cohen AD. The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study. J Am Acad Dermatol 2021;85:79-87. [PMID: 33744354 DOI: 10.1016/j.jaad.2021.02.087] [Reference Citation Analysis]